Table 2.
Laboratory evaluation and statistical significance
| SRP (group 1)
|
FMSRP (group 2)
|
|||||
|---|---|---|---|---|---|---|
| 1st stage (0) | 3rd stage (180 days) | Δ (0–180 days) | 1st stage (0) | 3rd stage (180 days) | Δ (0–180 days) | |
| TC (mg/dL) | 153.76±0.60 | 149.08±0.62# | 4.68±0.55 | 154.80±0.41 | 149.76±0.53# | 5.04±0.54 |
| LDL (mg/dL) | 85.83±0.53 | 90.78±0.70# | −4.95±0.12 | 85.12±0.46 | 81.92±0.62 | 3.20±0.15* |
| HDL (mg/dL) | 51.35±0.32 | 51.57±0.23 | −0.22±0.04 | 54.37±0.44 | 53.53±0.44 | 0.84±0.13 |
| TGs (mg/dL) | 82.94±0.86 | 75.85±0.80# | 7.09±0.83 | 76.93±0.70 | 71.15±0.61# | 5.78±0.86 |
| VLDL (mg/dL) | 16.51±0.17 | 15.21±0.15# | 1.30±0.16 | 15.35±0.14 | 14.30±0.11# | 1.05±0.18 |
| FGN (g/L) | 2.71±0.02 | 2.52±0.01# | 0.19±0.02 | 2.74±0.02 | 2.35±0.01# | 0.39±0.02 |
| CRP (mg/dL) | 0.61±0.04 | 0.20±0.01# | 0.41±0.04 | 0.12±0.01 | 0.20±0.01 | −0.08±0.01 |
| IL-6 (pg/mL) | 1.42±0.09 | 0.85±0.02# | 0.57±0.01 | 0.92±0.02 | 0.72±0.01# | 0.20±0.02 |
| TNF-α (pg/mL) | 12.39±0.9 | 15.79±1.43 | −3.38±0.08 | 13.44±0.70 | 17.73±1.30 | −4.29±0.13 |
#
Statistically significant difference between means within each of the treatment groups at P<0.05
*
statistically significant difference between the variation of the means (Δ) of the two treatment groups at P<0.05. Data are expressed as means ± standard error of the mean.
Abbreviations: TC, total cholesterol; HDL, high-density lipoprotein; TGs, triglycerides; VLDL, very-low-density lipoprotein; FGN, fibrinogen; CRP, C-reactive protein; IL, interleukin; TNF, tumor necrosis factor FMSRP, full-mouth scaling and root planing; SRP, scaling and root planing; LDL, low-density lipoprotein.